<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:08:39Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9945047" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9945047</identifier>
        <datestamp>2023-02-23</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9945047</article-id>
              <article-id pub-id-type="pmcid">PMC9945047</article-id>
              <article-id pub-id-type="pmc-uid">9945047</article-id>
              <article-id pub-id-type="pmid">36810174</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2022-064682</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2022-064682</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Mental Health</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1712</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleep–wake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-67565924" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6539-423X</contrib-id>
                  <name>
                    <surname>Wilson</surname>
                    <given-names>Chloe</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-64056187" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-9766-6700</contrib-id>
                  <name>
                    <surname>Carpenter</surname>
                    <given-names>Joanne Sarah</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-59004398" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-6404-7199</contrib-id>
                  <name>
                    <surname>Nichles</surname>
                    <given-names>Alissa</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-59004364" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7649-4711</contrib-id>
                  <name>
                    <surname>Zmicerevska</surname>
                    <given-names>Natalia</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-73779931" contrib-type="author">
                  <name>
                    <surname>Song</surname>
                    <given-names>Yun Ju Christine</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-80774422" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4891-4966</contrib-id>
                  <name>
                    <surname>McHugh</surname>
                    <given-names>Catherine</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-73780026" contrib-type="author">
                  <name>
                    <surname>Hamilton</surname>
                    <given-names>Blake</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-85998752" contrib-type="author">
                  <name>
                    <surname>Hockey</surname>
                    <given-names>Samuel</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-80775432" contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3805-2936</contrib-id>
                  <name>
                    <surname>Crouse</surname>
                    <given-names>Jacob</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-73802373" contrib-type="author">
                  <name>
                    <surname>Koethe</surname>
                    <given-names>Dagmar</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-29693264" contrib-type="author">
                  <name>
                    <surname>Scott</surname>
                    <given-names>Elizabeth M</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
                <contrib id="author-29693295" contrib-type="author">
                  <name>
                    <surname>Hickie</surname>
                    <given-names>Ian B</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="aff1"><institution content-type="department">Brain and Mind Centre</institution>, <institution>The University of Sydney</institution>, <addr-line content-type="city">Camperdown</addr-line>, <addr-line content-type="state">New South Wales</addr-line>, <country>Australia</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Chloe Wilson; <email>chloe.wilson@sydney.edu.au</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>21</day>
                <month>2</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>2</issue>
              <elocation-id>e064682</elocation-id>
              <history>
                <date date-type="received">
                  <day>12</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>27</day>
                  <month>1</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-02-21">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2022-064682.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2022-064682.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2022-064682.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Metformin is a medication likely to improve measures of cardiometabolic disturbance in young people with mental illness. Evidence also suggests metformin may improve depressive symptoms. This 52-week double-blind randomised control trial (RCT) aims to investigate the efficacy of metformin pharmacotherapy as an adjunct to a healthy lifestyle behavioural intervention in improving cardiometabolic outcomes, and depressive, anxiety and psychotic symptoms in youth with clinically diagnosed major mood syndromes.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>At least 266 young people aged 16–25 presenting for mental healthcare for major mood syndromes who are also at risk for poor cardiometabolic outcomes will be invited to participate in this study. All participants will engage in a 12-week sleep–wake, activity and metabolically focused behavioural intervention programme. As an adjunctive intervention, participants will receive either metformin (500–1000 mg) or placebo pharmacotherapy for 52 weeks.</p>
                  <p>Participants will undergo a series of assessments including: (1) self-report and clinician-administered assessments; (2) blood tests; (3) anthropometric assessments (height, weight, waist circumference and blood pressure); and (4) actigraphy. Univariate and multivariate tests (generalised mixed-effects models) will be used to examine changes in primary and secondary outcomes (and associations with predetermined predictor variables).</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>This study has been approved by the Sydney Local Health District Research Ethics and Governance Office (X22-0017). The results of this double-blind RCT will be disseminated into the scientific and broader community through peer-reviewed journals, conference presentations, social media and university websites.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p>Australian New Zealand Clinical Trials Registry (ANZCTR) Number: ACTRN12619001559101p, 12 November 2019.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>child &amp; adolescent psychiatry</kwd>
                <kwd>therapeutics</kwd>
                <kwd>depression &amp; mood disorders</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id>
                      <institution>National Health and Medical Research Council</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>511921, awarded to I.B.H</award-id>
                </award-group>
                <award-group id="funding-2">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Health &amp; Medical Research Council Emerging Leadership Fellowship</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>awarded to J.J.C</award-id>
                </award-group>
                <award-group id="funding-3">
                  <funding-source>
                    <institution-wrap>
                      <institution>Caroline Quinn Research Grant</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>awarded to JSC</award-id>
                </award-group>
                <award-group id="funding-4">
                  <funding-source>
                    <institution-wrap>
                      <institution>Liu McCabe Family Scholarship</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>awarded to CW</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BWL1" position="float">
              <caption>
                <title>Strengths and limitations of this study</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>This double-blind randomised control trial tests whether a medication (metformin) delivers long-term benefits beyond those achieved by behavioural intervention.</p>
                </list-item>
                <list-item>
                  <p>A range of physical and mental health outcomes are assessed, including cardiometabolic, anthropometric, sleep–wake and depressive symptoms.</p>
                </list-item>
                <list-item>
                  <p>The use of HOMA2-IR as the primary outcome measurement, may be a more sensitive indicator of metabolic abnormality in this cohort, compared with traditional measures (body mass index).</p>
                </list-item>
                <list-item>
                  <p>As all participants receive a sleep–wake, activity and metabolically focused behavioural intervention programme, there is no comparison of this behavioural intervention to a control group.</p>
                </list-item>
                <list-item>
                  <p>The behavioural intervention component of the study runs for 12 weeks whereas the medication period is 52 weeks. As such, the behavioural intervention may not be sufficient to instil long-term metabolic changes.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Youth with major mental illness often present with emerging cardiometabolic risk factors including insulin resistance and obesity.<xref rid="R1" ref-type="bibr">1–4</xref> The high prevalence of cardiometabolic abnormalities in youth with severe mental disorders is of concern as they are thought to be the leading contributor to the premature mortality and morbidity of individuals presenting with severe mental disorders.<xref rid="R5" ref-type="bibr">5 6</xref> While these cardiometabolic risk factors may emerge early on in care,<xref rid="R1" ref-type="bibr">1–4 7 8</xref> there is some evidence emerging to suggest there may be some bidirectional relationships. For example, research suggests that those with depression are more likely to develop obesity over time.<xref rid="R9" ref-type="bibr">9</xref> Another longitudinal study found that high fasting insulin levels in childhood are associated with increased risk for psychosis at age 24, and that increases in body mass index (BMI) during puberty are associated with a greater risk for depression at 24 years old.<xref rid="R10" ref-type="bibr">10</xref> The development of these cardiometabolic risk factors so early in the course of care for young people presenting with mental disorders is especially concerning. Thus, a significant challenge for clinicians is to target and develop interventions to manage and prevent the development of these cardiometabolic risk factors in young people with mental disorders.</p>
              <p>Key modifiable risk factors linked to the development of cardiometabolic abnormalities in this cohort include physical inactivity,<xref rid="R11" ref-type="bibr">11</xref> poor dietary habits<xref rid="R12" ref-type="bibr">12</xref> and poor sleep–wake cycle regulation.<xref rid="R13" ref-type="bibr">13</xref> Additionally, some psychotropic medication given to treat psychotic or affective symptoms are associated with weight gain, elevated blood lipids and insulin resistance.<xref rid="R14" ref-type="bibr">14</xref></p>
              <p>Metformin is an oral biguanide approved for the treatment of type 2 diabetes mellitus (T2DM) as monotherapy in children from 10 years of age and adolescents by the Australian Register of Therapeutic Goods. Metformin is expected to reduce hepatic glucose production, reduce intestinal absorption of glucose and enhance insulin sensitivity.<xref rid="R15" ref-type="bibr">15</xref> In non-psychiatric children and adolescents with obesity, meta-analytic evidence has shown that whether implemented in isolation or in combination with lifestyle interventions, metformin is associated with improvement in markers of BMI,<xref rid="R16" ref-type="bibr">16</xref> triglycerides,<xref rid="R16" ref-type="bibr">16</xref> fasting glucose,<xref rid="R17" ref-type="bibr">17</xref> low-density lipoprotein (LDL)-cholesterol,<xref rid="R17" ref-type="bibr">17</xref> total cholesterol<xref rid="R16" ref-type="bibr">16 18</xref> and T2DM.<xref rid="R19" ref-type="bibr">19</xref> There does however appear to be mixed evidence on the effect of metformin treatment on insulin resistance measures in non-psychiatric samples of adolescents,<xref rid="R17" ref-type="bibr">17</xref> either showing some or no improvement. Most studies on youth with psychiatric diagnoses have found that metformin improves weight or BMI.<xref rid="R20" ref-type="bibr">20–22</xref> However, less research has been conducted on other cardiometabolic risk factors in youth with psychiatric conditions.</p>
              <p>Furthermore, metformin has been suggested as a potential medication adjunct in youth mental illness, to manage some of the side effects associated with psychotropic medication usage<xref rid="R23" ref-type="bibr">23</xref> including, elevated lipids<xref rid="R24" ref-type="bibr">24</xref> and insulin resistance.<xref rid="R21" ref-type="bibr">21 25</xref> Metformin has also been linked to improved depressive and anxiety symptoms in young women with polycystic ovarian syndrome,<xref rid="R26" ref-type="bibr">26</xref> and improved mood symptoms in adults with major depressive disorder.<xref rid="R27" ref-type="bibr">27</xref></p>
              <p>Additionally, evidence is beginning to emerge of the benefits of metformin pharmacotherapy on affective symptoms. Specifically, metformin prescription has been linked to improved depressive and anxiety symptoms in female youths with polycystic ovarian syndrome.<xref rid="R26" ref-type="bibr">26</xref> Due to its link with neurogenesis,<xref rid="R28" ref-type="bibr">28</xref> metformin may also have the potential to improve mood states in those with major mood disorders. However, with limited research in this field, the utility of long-term metformin to improve both cardiometabolic abnormalities and mood symptoms in youth mental disorders has not been explored to its full potential and warrants further investigation.</p>
              <p>Lifestyle interventions are an effective non-pharmacological intervention option to manage drug-induced cardiometabolic disturbances in patients with psychiatric disorders and should be available pre-emptively to protect cardiometabolic health from the first presentation of illness. Psychoeducational or behavioural interventions focusing on healthy lifestyle habits including nutrition, physical activity and sleep practices have been shown to ameliorate both the physical and mental health concerns of young people with psychiatric disorders.<xref rid="R29" ref-type="bibr">29–34</xref> Several studies have administered metformin together with a comprehensive lifestyle intervention containing structured physical activity, nutritional advice or motivational support.<xref rid="R22" ref-type="bibr">22 35–43</xref> Results from these studies indicate that lifestyle interventions combined with metformin is superior to either intervention alone in reducing weight and BMI.<xref rid="R16" ref-type="bibr">16 22 44 45</xref></p>
              <p>However, lifestyle behavioural interventions alone may not sufficiently alleviate and prevent the poor cardiometabolic outcomes in young people with mood and psychotic syndromes. In fact, pharmacological cotherapies have already been shown to produce more meaningful clinical improvements above and beyond that of lifestyle interventions in alleviating and improving the cardiometabolic risk factors in youth. For example, in studies on overweight and obese youth, several of the studies involved receiving metformin together with a comprehensive lifestyle intervention involving structured physical activity, diet advice or motivational support.<xref rid="R35" ref-type="bibr">35–43</xref> Results from these studies indicate that lifestyle intervention combined with metformin is superior to either interventions alone in reducing measures of weight and BMI.<xref rid="R16" ref-type="bibr">16 22 44 45</xref> Compared with lifestyle interventions, metformin also appears to produce greater benefits in reducing fasting insulin levels and homeostatic model assessment of insulin resistance (HOMA1-IR) levels at 6, 12 and 24 months in overweight/obese non-diabetic children and adolescents.<xref rid="R46" ref-type="bibr">46</xref> Thus, metformin pharmacotherapy may assist in producing more clinically meaningful improvements in several cardiometabolic risk factors of concern in young people with clinically diagnosed mood and psychotic syndromes, however, further research is needed to understand the relationship between these factors over time.</p>
              <p>There is also evidence to indicate that the updated HOMA2-IR may be a more sensitive indicator of metabolic abnormality in this cohort.<xref rid="R3" ref-type="bibr">3</xref> By examining HOMA2-IR longitudinally, along with other cardiometabolic outcomes in this cohort, we may be able to demonstrate a more sensitive measure of cardiometabolic risk than previously recognised measures. Additionally, no studies have yet examined the effects of metformin pharmacotherapy on depressive, anxiety or psychotic symptoms in young people with major mood syndromes.</p>
              <p>Overall, this study aims to investigate the efficacy of metformin as an adjunct to a sleep–wake, activity and metabolically focused behavioural intervention programme targeted towards improving cardiometabolic outcomes and affective symptoms in young people presenting for mental healthcare for major mood syndromes. As a superiority trial, we also aim to determine whether the combined metformin pharmacotherapy and behavioural intervention is clinically better than the behavioural intervention in isolation.</p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <sec id="s2-1">
                <title>Patient and public involvement</title>
                <p>The study design, conduct and behavioural intervention module content was developed in consultation with representatives from the Brain and Mind Centre Youth Lived Experienced Working Group. Specifically, the module content was presented to the lived experience working group in a collaborative workshop, where module content was modified and optimised to ensure the suitability and relevance for this cohort. Patients or the public were not involved in the recruitment, conduct or dissemination plans of our research.</p>
              </sec>
              <sec id="s2-2">
                <title>Design and structure</title>
                <p>This is a phase IV double-blind randomised control trial (RCT), where participants are randomised to an adjunct medication with metformin or placebo. All participants will receive 52 weeks of metformin or placebo treatment along with a sleep–wake, activity and metabolically focused behavioural intervention programme in the first 12 weeks of the study. This behavioural intervention programme will involve structured nutritional, physical activity, sleep–wake and general healthy lifestyle information based on the Australian Guidelines of Physical Activity,<xref rid="R47" ref-type="bibr">47</xref> the Australian Guide to Healthy Eating<xref rid="R48" ref-type="bibr">48</xref> and published circadian research findings specific to youth mental illness.<xref rid="R49" ref-type="bibr">49–52</xref> This information will be delivered for approximately 1 hour each fortnight over six online or face-to-face modules (week 1, 3, 5, 7, 9 and 11). These modules will cover the topics shown in <xref rid="T1" ref-type="table">table 1</xref>. From weeks 1–12, participants will receive a weekly monitoring phone call to aid their engagement and ongoing participation. After week 12, participants will receive monthly phone calls to monitor symptoms and medication adherence. Participants will also receive a summary sheet containing the information from the modules that they can refer to throughout the remainder of the trial. As such, the information from the behavioural intervention will not be repeated across the remainder of the intervention, however participants will be given the opportunity to discuss their behavioural changes and goals within the ongoing monthly phone calls.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Sleep–wake, activity and metabolically focused behavioural intervention modules</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Session</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Topics to be covered</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">1. Body clock and sleep–wake cycle regulation for mental health (part 1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Establishing a healthy mindset and goal setting</p>
                            </list-item>
                            <list-item>
                              <p>How the brain and body are connected</p>
                            </list-item>
                            <list-item>
                              <p>Role of melatonin</p>
                            </list-item>
                            <list-item>
                              <p>Importance of the brain and body clock and sleep–wake cycle regulation</p>
                            </list-item>
                            <list-item>
                              <p>How the brain and body clock coordinates all the biological systems</p>
                            </list-item>
                            <list-item>
                              <p>How to regulate the sleep–wake cycle for example, via gradual sleep–wake rescheduling</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">2. Body clock and sleep–wake cycle regulation for mental health (part 2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Healthy sleep–wake behaviours</p>
                            </list-item>
                            <list-item>
                              <p>How lifestyle factors and behaviours influence the brain and body clock for example, exercise, light exposure, sleep environment, sleep regularisation, naps, foods, stress, anxiety and mood</p>
                            </list-item>
                            <list-item>
                              <p>Sleep wake–cycle regulation tip for example, consistent sleep–wake times, avoiding naps and exercise regularly</p>
                            </list-item>
                            <list-item>
                              <p>Limiting screen time in the evening</p>
                            </list-item>
                            <list-item>
                              <p>Creating a sleep routine</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">3. Physical activity for mental health (part 1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Benefits of physical activity for physical and mental health </p>
                            </list-item>
                            <list-item>
                              <p>Outline of Australian Physical Activity Guidelines </p>
                            </list-item>
                            <list-item>
                              <p>Identifying and challenging barriers to engaging in physical activity</p>
                            </list-item>
                            <list-item>
                              <p>Timing of physical activity</p>
                            </list-item>
                            <list-item>
                              <p>Tips for starting exercise</p>
                            </list-item>
                            <list-item>
                              <p>Increasing incidental activity, reducing sitting time</p>
                            </list-item>
                            <list-item>
                              <p>Establishing an activity schedule</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">4. Physical activity for mental health (part 2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Working out anywhere</p>
                            </list-item>
                            <list-item>
                              <p>Fitting in exercise throughout your day</p>
                            </list-item>
                            <list-item>
                              <p>Finding the motivation</p>
                            </list-item>
                            <list-item>
                              <p>Concept of energy in vs energy out</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">5. Nutrition for mental health (part 1)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Energy in vs energy out and creating a healthy balance</p>
                            </list-item>
                            <list-item>
                              <p>Outline of Australian Dietary Guidelines</p>
                            </list-item>
                            <list-item>
                              <p>Creating a healthy eating plate</p>
                            </list-item>
                            <list-item>
                              <p>Standard serving sizes/portion sizes</p>
                            </list-item>
                            <list-item>
                              <p>Alcohol and mental health</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">6. Nutrition for mental health (part 2)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Timing of meals</p>
                            </list-item>
                            <list-item>
                              <p>Healthy snacking</p>
                            </list-item>
                            <list-item>
                              <p>Meal preparation</p>
                            </list-item>
                            <list-item>
                              <p>Making healthy choices when eating out at restaurants</p>
                            </list-item>
                            <list-item>
                              <p>Managing comfort eating</p>
                            </list-item>
                            <list-item>
                              <p>Making sustainable choices</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                </table-wrap>
                <p>Participants will be asked to wear an actigraph (GENEActiv; Activinsights, Kimbolton, UK) on the non-dominant wrist to collect 24-hour sleep–wake and physical activity parameters during weeks 1–2, 11–12, 25–26, 37–38 and 51–52. In weeks 1, 12, 26, 38 and 52, the following will also be collected: fasting blood tests to measure metabolic, immune and hormonal markers, anthropometric assessments (blood pressure, height, weight and waist circumference), self-report and clinician-administered assessments to assess various mental illness symptoms and physical activity engagement. Blood tests for genetic analysis will be collected in week 1 only. All assessments including the self-report questionnaires and clinician-rated assessments are expected to take approximately 2 hours at each time point.</p>
                <p>Most of these self-report and clinician-administered assessments are part of the standardised assessment battery developed for the Youth Mental Health Tracker as part of the Brain and Mind Centre (BMC) multidimensional research framework.<xref rid="R53" ref-type="bibr">53</xref> The multidimensional outcome framework was developed to assess a comprehensive range of measures in individuals presenting to care across a range of domains important to mental health outcomes. All observational and interventional youth mental health research at the BMC uses a standardised set of measures within this framework. These assessments are part of an ongoing larger study for all young people presenting for mental healthcare to improve the outcomes of their clinical care. The schedule of enrolment, interventions and assessment time points can be seen in <xref rid="T2" ref-type="table">table 2</xref>. The participant will begin the trial the day they are enrolled (week 1), and will cease the trial after Week 52.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Schedule of enrolment, interventions and assessment time points</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="3" colspan="1"/>
                        <td align="left" valign="bottom" rowspan="1" colspan="12">Study phase</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="2">Prerandomisation</td>
                        <td align="left" valign="top" rowspan="1" colspan="6">Behavioural intervention week</td>
                        <td align="left" valign="top" rowspan="1" colspan="4">Post-trial week</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Screening</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">Enrolment (week 1)</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">1</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">3</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">5</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">7</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">9</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">11</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">12</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">26</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">38</td>
                        <td align="char" char="." valign="top" rowspan="1" colspan="1">52</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="13">
                          <bold>Study procedures</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Phone screening</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Informed consent</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent"> </named-content><named-content content-type="indent"> </named-content><named-content content-type="indent"> </named-content><named-content content-type="indent"> </named-content><named-content content-type="indent"> </named-content>x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Meet inclusion criteria</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Randomization allocation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="13">
                          <bold>Intervention phases</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Actigraphy</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="2">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="2">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="2">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Metformin/placebo</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="10">
                          <inline-graphic xlink:href="bmjopen-2022-064682ilf01.jpg"/>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Psychoeducation sessions</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="13">
                          <bold>Self-report questionnaires</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Self-report questionnaires</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="13">
                          <bold>Clinician-administered assessments</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Genetic testing</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Psychological assessments</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Physical/blood assessments</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x*</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1"> </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">x</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T2_FN1">
                      <p>*Physical assessments and/or blood tests may need to be conducted to confirm selection criteria.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-3">
                <title>Randomisation, dosage and treatment arms</title>
                <p>The participants will be prerandomised in a 1:1 ratio via a block randomisation sequence of four and allocated to one of the two treatment arms: oral metformin (500 mg–1000 mg daily) or placebo. The packaging of the study medication will be prerandomised and contain a randomisation number. This dosage is based on previous studies with similar cohorts<xref rid="R20" ref-type="bibr">20</xref> and guidelines on metformin prescription in youth.<xref rid="R54" ref-type="bibr">54 55</xref> After 2 weeks, the participant’s tolerability (especially gastrointestinal side effects) will be assessed by the study doctor and where appropriate the dosage will be titrated up to 1000 mg per day. Participants, their healthcare practitioners (psychiatrists, psychologists, general practitioners, exercise physiologists and/or social workers) and research staff will be masked to the treatment allocation.</p>
              </sec>
              <sec id="s2-4">
                <title>Blinding</title>
                <p>Participants, their healthcare providers and research staff (including outcome assessors) will be masked to treatment allocation. Unblinding of study medication may occur in the instance of a serious adverse event and for safety reasons. The decision to unblind is at the discretion of the principal investigator. The dispensing clinician will then be able to inform study staff whether the participant was on the active or placebo at the time.</p>
              </sec>
              <sec id="s2-5">
                <title>Setting, recruitment and informed consent</title>
                <p>This is a single-site, double-blind RCT, conducted at the BMC (including <italic toggle="yes">headspace</italic> Camperdown and Early Intervention and High Intensity Services) at the University of Sydney (Sydney, Australia). These clinics comprise a mix of primary-level mental healthcare as well as more specialised services. As such, these clinics attract young people with a range of mental health problems including those with subthreshold and full-threshold mental disorders.</p>
                <p>All treating clinicians will be made aware of the study and eligibility criteria and will inform all suitable young people presenting for care at these services to participate in the study. Research staff will obtain written informed consent from interested young persons to participate in the sleep–wake, activity and metabolically focused behavioural intervention programme. The research team will make explicit to any potential participants both verbally and in writing (in the participant information and consent form) that participation is voluntary. They will be assured that their decision whether to participate will not affect their current or future relationship with the researchers or anyone else at The University of Sydney nor their current or future involvement with the mental health service. Participants will also be made aware that they are free to withdraw from the study at any time by contacting research staff.</p>
              </sec>
              <sec id="s2-6">
                <title>Selection criteria</title>
                <p>Young people will be invited into the double-blind RCT, based on the following inclusion criteria:</p>
                <list list-type="order">
                  <list-item>
                    <p>aged between 16 and 25;</p>
                  </list-item>
                  <list-item>
                    <p>a current diagnosis of a major mood syndrome (including anxiety, depression, bipolar disorder and affective psychosis) according to the Diagnostic and Statistical Manual of Mental Disorders, version V (DSM-V) criteria using the Structured Clinical Interview for DSM-V (SCID).</p>
                  </list-item>
                  <list-item>
                    <p>BMI ≥25;</p>
                  </list-item>
                </list>
                <p>and <bold>at least one</bold> (≥1) of the following conditions:</p>
                <list list-type="order">
                  <list-item>
                    <p>HOMA2-IR value≥1.5;</p>
                  </list-item>
                  <list-item>
                    <p>currently on and/or commencing psychotropic medication (antipsychotics, antidepressants, mood stabilisers) under psychiatric supervision and/or mental illness has reached Stage 2 ‘Discrete Disorders’ in the clinical staging model framework for mood and psychotic syndromes.<xref rid="R56" ref-type="bibr">56 57</xref></p>
                  </list-item>
                </list>
                <p>The exclusion criteria are:</p>
                <list list-type="roman-lower">
                  <list-item>
                    <p>lifetime use of metformin or any other glucose lowering medication;</p>
                  </list-item>
                  <list-item>
                    <p>lifetime diagnosis of T1 or T2DM diabetes (gestational diabetes accepted);</p>
                  </list-item>
                  <list-item>
                    <p>intellectual disability (at the discretion of a clinical psychologist or psychiatrist);</p>
                  </list-item>
                  <list-item>
                    <p>major neurological disorder, medical illness which impacts on cognition, and/or a history of sustained head injury;</p>
                  </list-item>
                  <list-item>
                    <p>inadequate English language skills;</p>
                  </list-item>
                  <list-item>
                    <p>a current alcohol or substance use disorder that impairs the individual’s ability to give informed consent and/or requires acute clinical treatment;</p>
                  </list-item>
                  <list-item>
                    <p>a risk of serious self-harm (as assessed by the study doctor);</p>
                  </list-item>
                  <list-item>
                    <p>an acute psychotic or manic episode that impairs the individual’s ability to give informed consent; or</p>
                  </list-item>
                  <list-item>
                    <p>any contraindications to metformin treatment (described below).</p>
                  </list-item>
                </list>
                <p>Participants will not be allowed to enter the study if they possess any of the following contraindications to metformin treatment:</p>
                <list list-type="roman-lower">
                  <list-item>
                    <p>juvenile diabetes mellitus that is uncomplicated and well-regulated on insulin;</p>
                  </list-item>
                  <list-item>
                    <p>diabetes mellitus regulated by diet alone;</p>
                  </list-item>
                  <list-item>
                    <p>during or immediately following surgery where insulin is essential;</p>
                  </list-item>
                  <list-item>
                    <p>hypersensitivity to metformin or any of its ingredients;</p>
                  </list-item>
                  <list-item>
                    <p>hypersensitivity to biguanides;</p>
                  </list-item>
                  <list-item>
                    <p>diabetic ketoacidosis, diabetic pre-coma;</p>
                  </list-item>
                  <list-item>
                    <p>renal failure or renal dysfunction (creatinine clearance&lt;60 mL/min);</p>
                  </list-item>
                  <list-item>
                    <p>acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock or intravascular administration of iodinated contrast agents;</p>
                  </list-item>
                  <list-item>
                    <p>acute or chronic disease which may cause tissue hypoxia such as cardiac failure, recent myocardial infarction, respiratory failure, pulmonary embolism, shock, acute significant blood loss, sepsis, gangrene or pancreatitis,</p>
                  </list-item>
                  <list-item>
                    <p>elective major surgery;</p>
                  </list-item>
                  <list-item>
                    <p>severe hepatic insufficiency;</p>
                  </list-item>
                  <list-item>
                    <p>acute alcohol intoxication or alcoholism; or</p>
                  </list-item>
                  <list-item>
                    <p>lactation.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-7">
                <title>Study discontinuation and safety</title>
                <p>Participants will be monitored for exclusion criteria and contraindications to metformin treatment in weeks 12, 26, 38 and 52. Where the participant meets any of the exclusion criteria throughout the trial, or they experience any contraindications to metformin prescription, they will be withdrawn from the study immediately, discontinued treatment and followed up by the study doctor. The participants general medicine practitioner will be notified (with consent, via email) and where necessary, counselling or other mental health support will be made available to support the young person. The principal investigator will ensure that follow-up of the participant is appropriate to the nature of any event, and that it continues until resolution. Participants who prematurely withdraw from the study or are discontinued from the study treatment will not be replaced.</p>
                <p>An independent Data and Safety Monitoring Committee (DSMC) has been assembled to monitor the progress, safety, adverse events and efficacy of this clinical trial and provide critical evaluation and recommendations to principal investigators and all sponsors of this trial. The DSMC will meet every 6 months throughout this trial and review cumulative study data to evaluate study conduct, the scientific validity and data integrity of the study including safety of this trial.</p>
              </sec>
              <sec id="s2-8">
                <title>Study objectives</title>
                <sec id="s2-8-1">
                  <title>Primary</title>
                  <p>To assess the efficacy of metformin pharmacotherapy as an adjunct to a healthy lifestyle sleep–wake, activity and metabolically focused behavioural intervention programme in improving HOMA2-IR scores of young people seeking treatment for mental health-related issues.</p>
                </sec>
                <sec id="s2-8-2">
                  <title>Secondary</title>
                  <p>To assess the efficacy of metformin pharmacotherapy as an adjunct to a healthy lifestyle sleep–wake, activity and metabolically focused behavioural intervention programme in improving cardiometabolic health measurements (blood pressure, fasting glucose, triglycerides, cholesterol levels, BMI and waist circumference), and depressive, anxiety and psychotic symptoms of young people seeking treatment for mental health-related issues.</p>
                  <p>To assess if changes in cardiometabolic health risk factors (fasting insulin, fasting glucose, triglycerides, HOMA2-IR, cholesterol, blood pressure, BMI and waist circumference) are associated with changes in affective (depressive and anxiety) symptom severity.</p>
                </sec>
                <sec id="s2-8-3">
                  <title>Tertiary</title>
                  <p>To assess if changes in mood symptoms or changes in cardiometabolic parameters following adjunctive metformin treatment are associated with a range of multidimensional outcome measures in young people seeking treatment for mental health concerns. This includes mental illness symptoms, self-harm and suicidal thoughts and behaviours, physical health parameters, alcohol and substance use, inflammatory markers, hormonal response and genetic markers.</p>
                </sec>
              </sec>
              <sec id="s2-9">
                <title>Measures</title>
                <p>The following measures have been described in more extensive detail in our previous protocol outlining the pilot study of the behavioural intervention component.<xref rid="R58" ref-type="bibr">58</xref> Key outcome measures targeted for this study are highlighted in <bold>bold type</bold>. Please refer to <xref rid="T3" ref-type="table">table 3</xref> which summarises the primary, secondary and tertiary outcome measures.</p>
                <table-wrap position="float" id="T3">
                  <label>Table 3</label>
                  <caption>
                    <p>Outcome measures</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Measures</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Primary</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>HOMA2-IR</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Secondary</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Fasting glucose</p>
                            </list-item>
                            <list-item>
                              <p>Fasting insulin</p>
                            </list-item>
                            <list-item>
                              <p>Triglycerides</p>
                            </list-item>
                            <list-item>
                              <p>HDL cholesterol level</p>
                            </list-item>
                            <list-item>
                              <p>LDL cholesterol</p>
                            </list-item>
                            <list-item>
                              <p>Total cholesterol</p>
                            </list-item>
                            <list-item>
                              <p>HbA1c</p>
                            </list-item>
                            <list-item>
                              <p>Inflammatory markers (IL-1β, IL-2, IL-6, C reactive proteins, IFN-γ, TNF-α)</p>
                            </list-item>
                            <list-item>
                              <p>Hormonal markers (prolactin, oestradiol, DHEAS, testosterone, LH, FSH, SHBG, AMH, serum cortisol and 17OHP)</p>
                            </list-item>
                            <list-item>
                              <p>Blood pressure</p>
                            </list-item>
                            <list-item>
                              <p>BMI</p>
                            </list-item>
                            <list-item>
                              <p>Waist circumference measurement</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>The Brief Psychiatric Rating Scale (BPRS)</p>
                            </list-item>
                            <list-item>
                              <p>Kessler Psychological Distress Scale (K-10)</p>
                            </list-item>
                            <list-item>
                              <p>Quick Inventory of Depressive Symptomatology-self-report (QIDS-SR)</p>
                            </list-item>
                            <list-item>
                              <p>Overall Anxiety Severity Impairment Scale (OASIS)</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Tertiary</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <list list-type="bullet">
                            <list-item>
                              <p>Diagnostic assessment</p>
                            </list-item>
                            <list-item>
                              <p>Clinical staging</p>
                            </list-item>
                            <list-item>
                              <p>Pathophysiological mechanisms</p>
                            </list-item>
                            <list-item>
                              <p>Clinical global impression (CGI)</p>
                            </list-item>
                            <list-item>
                              <p>The Young Mania Rating Scale (YMRS)</p>
                            </list-item>
                            <list-item>
                              <p>Social and Occupational Assessment Scale (SOFAS)</p>
                            </list-item>
                            <list-item>
                              <p>Comprehensive Assessment of At-Risk Mental States (CAARMS)</p>
                            </list-item>
                            <list-item>
                              <p>Somatic and Psychological Health Report (SPHERE 12)</p>
                            </list-item>
                            <list-item>
                              <p>Pittsburgh Sleep Quality Index (PSQI)</p>
                            </list-item>
                            <list-item>
                              <p>The Insomnia Severity Index (ISI)</p>
                            </list-item>
                            <list-item>
                              <p>International Physical Activity Questionnaire (IPAQ)</p>
                            </list-item>
                            <list-item>
                              <p>Suicidal Ideation Attributes Scale (SIDAS)</p>
                            </list-item>
                            <list-item>
                              <p>WHO Alcohol, Smoking and Substance Involvement Screening Test (WHO-ASSIST)</p>
                            </list-item>
                            <list-item>
                              <p>Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)</p>
                            </list-item>
                            <list-item>
                              <p>Eating disorder examination (EDE)</p>
                            </list-item>
                            <list-item>
                              <p>Rosenberg Self-Esteem Scale (RSES)</p>
                            </list-item>
                            <list-item>
                              <p>Client Satisfaction Questionnaire-8 (CSQ-8)</p>
                            </list-item>
                            <list-item>
                              <p>The Simple Physical Activity Questionnaire (SIMPAQ)</p>
                            </list-item>
                            <list-item>
                              <p>Genetic variance via blood test</p>
                            </list-item>
                            <list-item>
                              <p>Hormonal markers (prolactin, oestradiol, DHEAS, testosterone, LH, FSH, SHBG, AMH, serum cortisol and 17OHP) measured via the fasting metabolic blood test</p>
                            </list-item>
                            <list-item>
                              <p>Actigraphy parameters via wrist-worn GENEActiv actigraph for a range of sleep–wake parameters including sleep onset time, sleep offset time, total sleep time (duration), wake after sleep onset, sleep efficiency, intra-daily stability/variability and total number of minutes moderate activity, total number of minutes vigorous activity and total number of sedentary minutes</p>
                            </list-item>
                            <list-item>
                              <p>Programme feedback questionnaire</p>
                            </list-item>
                          </list>
                        </td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T3_FN1">
                      <p>AMH, <bold>anti-mullerian hormone</bold>; DHEAS, dehydroepiandrosterone sulfate; FSH, <bold>follicle stimulating hormone</bold>; HDL, high-density lipoprotein; HOMA2-IR, homeostatic model assessment of insulin resistance; IFN, interferon; IL, interleukin; LDL, low-density lipoprotein; LH, <bold>luteinizing hormone</bold>; SHBG, <bold>sex hormone binding globulin</bold>; TNF, tissue necrosis factor.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-10">
                <title>Clinician-rated assessments</title>
                <list list-type="order">
                  <list-item>
                    <p><italic toggle="yes">Diagnostic assessment</italic>: The SCID-5<xref rid="R59" ref-type="bibr">59</xref> will be used to identify any DSM-V disorders.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Physical health, mental health, family health and treatment history:</italic> current and past medical history will be assessed including current medication and any changes in physical and/or mental health treatment being received throughout the trial.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">The Brief Psychiatric Rating Scale (BPRS)</italic><xref rid="R60" ref-type="bibr">60</xref>: the BPRS is used to assess psychiatric symptoms including depression, anxiety, hallucinations, delusions and unusual behaviour.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Clinical staging</italic><xref rid="R57" ref-type="bibr">57</xref>: this framework classifies individuals according to the presentation of their mental illness in three stages—those in the earliest phases with non-specific clinical presentations (Stage 1a ‘seeking help’), those at greater-risk with more specific, subthreshold presentations (Stage 1b ‘attenuated syndromes’) and those who have already reached a threshold for a progressive or recurrent disorder meeting diagnostic criteria (Stage 2, 3 or 4).<xref rid="R57" ref-type="bibr">57 61–63</xref></p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Pathophysiological mechanisms</italic><xref rid="R64" ref-type="bibr">64</xref>: the pathophysiological model suggests three putative pathways of illness: (i) neurodevelopmental psychosis, (ii) circadian-bipolar spectrum, or (iii) hyperarousal-anxious depression subtypes.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Clinical Global Impression (CGI</italic><xref rid="R65" ref-type="bibr">65</xref><italic toggle="yes">)</italic>: the CGI assesses a young person’s global functioning in context of their history, psychosocial circumstances, symptoms and behaviour.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">The Young Mania Rating Scale (YMRS)</italic><xref rid="R66" ref-type="bibr">66</xref>: the YMRS is an 11-item questionnaire measuring manic episode symptom severity.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">The Simple Physical Activity Questionnaire (SIMPAQ)</italic><xref rid="R67" ref-type="bibr">67</xref>: the SIMPAQ is a 5-item clinical tool designed to assess physical activity levels.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Suicidal ideation and behaviour:</italic> acute suicidal behaviour will be assessed by item 7.3 of the Comprehensive Assessment of At-Risk Mental States (CAARMS).<xref rid="R68" ref-type="bibr">68</xref></p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Social and Occupational Assessment Scale (SOFAS)</italic><xref rid="R38" ref-type="bibr">38</xref>: the SOFAS is an assessment of the participant’s current social and occupational functioning. Scores range from 0 to 100, with lower scores indicating poorer functioning.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-11">
                <title>Self-report questionnaires</title>
                <list list-type="order">
                  <list-item>
                    <p><italic toggle="yes">Demographics</italic>: basic demographic information will be collected including details of work and education, ethnicity, living circumstances, relationship status and physical health (height, weight and waist circumference).</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Kessler Psychological Distress Scale (K-10)</italic><xref rid="R69" ref-type="bibr">69 70</xref>: this 10-item scale provides a global measure of anxiety and depressive symptoms over a 4-week period.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">International Physical Activity Questionnaire (IPAQ)-short version</italic><xref rid="R71" ref-type="bibr">71 72</xref>: the short version of the International Physical Activity Questionnaires (IPAQ) is a 7-item questionnaire calculates the amount of time spent engaging in various intensities of physical activity.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Somatic and Psychological Health Report (SPHERE 12)</italic><xref rid="R73" ref-type="bibr">73</xref>: the SPHERE 12 assesses six psychological (PSYCH subscale), and six physical and fatigue symptoms (SOMA subscale) to identify anxiety, depression and somatisation symptoms.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Sleep–wake cycle and chronotype</italic>: six questions will be asked concerning sleeping patterns and feelings when waking up based on the Pittsburgh Sleep Quality Index (PSQI),<xref rid="R74" ref-type="bibr">74</xref> and Munich Chrono Type Questionnaire (MCTQ).<xref rid="R75" ref-type="bibr">75</xref></p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Pittsburgh Sleep Quality Index (PSQI)</italic><xref rid="R74" ref-type="bibr">74</xref>: he PSQI is a 24-item self-report questionnaire assessing sleep quality and patterns of sleep.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">The Insomnia Severity Index (ISI)</italic><xref rid="R76" ref-type="bibr">76</xref>: this 7-item questionnaire assesses sleep problems, daily functioning and impairment attributed to the sleep problem, and the degree of distress or concern caused by the sleep problem.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Suicidal Ideation Attributes Scale (SIDAS)</italic><xref rid="R77" ref-type="bibr">77</xref>: the SIDAS is a 5-item self-report questionnaire assessing suicidal ideology over the last month.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Quick Inventory of Depressive Symptomatology-self-report (QIDS-SR)</italic><xref rid="R78" ref-type="bibr">78</xref>: the QIDS assesses symptoms of a major depressive episode.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Overall Anxiety Severity Impairment Scale (OASIS</italic>)<xref rid="R79" ref-type="bibr">79</xref>: the OASIS is a 5-item self-report measure used to assess the frequency and intensity of anxiety symptoms.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">WHO Alcohol, Smoking and Substance Involvement Screening Test (WHO-ASSIST</italic>)<xref rid="R80" ref-type="bibr">80 81</xref>: the ASSIST (V.3.1) is an 8-item questionnaire screening for use of drugs and alcohol.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)</italic><xref rid="R82" ref-type="bibr">82</xref>: the AUDIT-C is a 3-item scale measuring alcohol consumption.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Eating Disorder Examination (EDE)</italic><xref rid="R83" ref-type="bibr">83 84</xref>: this self-report questionnaire assesses current eating disorder behaviours, including binge eating, purging and strict dieting or fasting.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Rosenberg Self-Esteem Scale (RSES)</italic><xref rid="R85" ref-type="bibr">85</xref>: the RSES is a 10-item self-report measure of self-esteem, self-worth or self-acceptance designed specifically for use in adolescent populations.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Client Satisfaction Questionnaire-8 (CSQ-8)</italic><xref rid="R86" ref-type="bibr">86</xref>: the CSQ assesses level of satisfaction with care.</p>
                  </list-item>
                  <list-item>
                    <p><italic toggle="yes">Feedback Questionnaire</italic>: this is an investigator-developed questionnaire specifically relating to the feasibility and acceptability of the sleep–wake, activity and metabolically focused behavioural intervention programme and the overall metformin treatment programme.</p>
                  </list-item>
                </list>
              </sec>
              <sec id="s2-12">
                <title>Blood markers</title>
                <p>Blood samples are to be collected in a fasting state between 8:00 am and 10:00 am by a trained phlebotomist at weeks 1,12, 26, 38 and 52. Metabolic variables of interest include <bold>fasting glucose; fasting insulin, and blood lipids (including triglycerides and total, high-density lipoprotein (HDL) and LDL cholesterol levels). Insulin resistance</bold> will be estimated using the updated homeostatic model assessment (<bold>HOMA2-IR</bold>) using iHOMA2 software V.8.8<xref rid="R87" ref-type="bibr">87</xref> from fasting blood test results.</p>
                <p>Hormonal markers measured include progesterone, prolactin, oestradiol, dehydroepiandrosterone sulfate, testosterone, leutenising hormone, follicle stimulating hormone, sex hormone binding globulin, anti-mullerian hormone, serum cortisol and 17-hydroxyprogesterone. Inflammatory markers measured include interleukin (IL)-1β, IL-2, IL-6, interferon (IFN)-γ, tissue necrosis factor (TNF)-α and C reactive protein.</p>
                <p>Other blood measures to be collected for monitoring purposes include <bold>HbA1c</bold>, full blood count, urea, electrolytes, liver function test, CRP, erythrocyte sedimentation rate, antinuclear antibodies, antineutrophil cytoplasmic antibodies, thyroid autoantibodies, free T4 markers, vitamin D, vitamin B<sub>12</sub>, folate, iron, thyroid stimulating hormone, calcium (Ca), magnesium (Mg) and phosphate (PO<sub>4</sub>) levels.</p>
              </sec>
              <sec id="s2-13">
                <title>Genetic variants</title>
                <p>In week 1, genetic material will be obtained from a sample of whole blood to extract DNA for genetic analysis. These samples will be collected by clinical research staff and processed at the Institute for Molecular Biosciences, University of Queensland to identify single-nucleotide polymorphisms associated with psychiatric and/or cardiometabolic traits. Genetic information will be analysed to examine associations between genetic risk variants and cardiometabolic outcomes.</p>
              </sec>
              <sec id="s2-14">
                <title>Anthropometric assessments</title>
                <p>Measures of <bold>blood pressure, height and weight</bold> will be collected in weeks 1, 12, 26, 38 and 52 via direct measurement by a clinician or research staff. <bold>BMI</bold> will be calculated using the formula: weight(kg) ÷ height(m).<xref rid="R2" ref-type="bibr">2</xref>
<bold>Waist circumference</bold> is measured with the participant standing up, to the nearest 1 cm with a measuring tape at the midpoint between the bottom of the rib cage and above the top of the iliac crest (hip bone) at the end of the participant’s normal respiration.</p>
              </sec>
              <sec id="s2-15">
                <title>24-Hour sleep–wake and physical activity profiling</title>
                <p>All participants will wear wrist-mounted actigraphy recording devices (GENEActiv Sleep device; Activinsights, Kimbolton, UK) to record motor activity over a 2-week period during weeks 1–2, 12–13, 26–27, 38–39 and 51–52. The data collected from these devises will provide an estimation of sleep and physical activity patterns based on validated algorithms.<xref rid="R88" ref-type="bibr">88</xref> Key measures include <bold>sleep onset time, sleep offset time, sleep midpoint,</bold> sleep efficiency, wake after sleep onset (number of minutes during the sleep period scored as awake) and total sleep time (number of minutes during the sleep period scored as sleep).</p>
                <p>Physical activity levels will be assessed through the GENEActiv devices calculates as gross motor activity per day (milli‐gravity (mg), 1g=9.81 m/s<sup>2</sup>) and <bold>minutes of moderate-to-vigorous physical activity per day</bold> (defined as the sum of 1‐minute epochs in which gross motor activity is larger than 125 mg) as described in other studies.<xref rid="R88" ref-type="bibr">88</xref> The GENEActiv devices have been used widely in clinical research and validated against several types of accelerometry-based activity monitors<xref rid="R89" ref-type="bibr">89–92</xref> as well as for sleep–wake scoring.<xref rid="R93" ref-type="bibr">93 94</xref></p>
              </sec>
              <sec id="s2-16">
                <title>Sample size/power calculation</title>
                <p>One study investigating the effect of metformin on HOMA1-IR levels in adolescents found an effect size of 0.68 after 12 months of treatment.<xref rid="R46" ref-type="bibr">46</xref> We conservatively estimated that the correlation coefficient would be smaller, around 0.40 (ie, a medium effect size), taking into account the effects of the sleep–wake, activity, and metabolically focused behavioural intervention. Assuming the following parameters (power analyses completed in G*Power V.3.1.9.4): two-tailed, difference between two independent means model with a power of 0.90, an effect size of 0.4 and an alpha level of 0.05, sample size of 266 (133 in each group) will be sufficient to detect an effect.</p>
              </sec>
              <sec id="s2-17">
                <title>Data analysis plan</title>
                <p>All data will be deidentified and entered into a secure password-protected database accessible only by authorised study staff. Statistical analyses were conducted usin R statistical software.</p>
                <sec id="s2-17-1">
                  <title>Univariate analyses</title>
                  <p>Change in HOMA2-IR score (primary objective) will be analysed via a change in mean score between the metformin and placebo groups via an independent samples t-test, with significance set at α=0.05. Similarly, changes in cardiometabolic measures (blood pressure, fasting glucose, fasting insulin, HOMA2-IR, cholesterol levels, BMI and waist circumference) and depressive, anxiety and psychotic symptoms (secondary objective) will be assessed via independent samples t-tests, with significance set at α=0.05. Differences in cardiometabolic outcome change scores according to psychiatric diagnosis will be assessed via analysis of variance, with significance levels set at α=0.05.</p>
                  <p>Finally, correlations will be examined between cardiometabolic parameters and the following (tertiary objective): depressive, anxiety and psychotic symptoms, mental illness symptoms, self-harm and suicidal thoughts and behaviours, physical health parameters, alcohol and substance use, inflammatory markers, hormonal response and genetic markers, via Pearson’s or Spearman’s correlations tests based on normative or non-normative data distribution respectively.</p>
                </sec>
                <sec id="s2-17-2">
                  <title>Multivariate analyses</title>
                  <p>Generalised linear mixed-effects models (using the R package nlme or lme4) will be used to examine changes in primary and secondary outcomes measures over the trial. Models will be fitted iteratively, starting first with an unconditional ‘base’ model (testing both linear and quadratic trends for longitudinal outcomes), and building in complexity towards a random intercepts and random effects model (with goodness-of-fit checks (eg, likelihood ratio test) to ensure model structural changes provide an improved fit to the data). An intention-to-treat analysis will be adopted to use all available data (including for participants that drop out); missing follow-up data will be handled using maximum-likelihood estimation. Conditional models will examine potential interindividual differences in both intercepts and slopes (ie, rate of change) as a function of several predetermined factors (age, sex, randomisation group, cardiometabolic factors, psychiatric diagnosis, clinical stage, psychotropic medication, depressive, anxiety and psychotic symptoms). Model coefficients will be presented with 95% CIs and parameter-specific p-values.</p>
                </sec>
              </sec>
              <sec id="s2-18">
                <title>Ethics and dissemination</title>
                <p>The Sydney Local Health District (RPAH Division) Human Research Ethics Committee (HREC) Committee has approved this study (X22-0017). The study will be conducted in compliance with all stipulations of the protocol, the conditions of ethics committee approval, the NHMRC National Statement on Ethical Conduct in Human Research and the Good Clinical Practice guidelines.</p>
                <p>The metformin treatment and behavioural intervention programme is designed as an adjunct, not an alternative, to standard clinical treatments offered by the youth mental health services. As such, all participants are encouraged to continue to follow the healthcare advice of their treating clinicians and to remain in their care, as well as participating in the sleep–wake, activity and metabolically focused behavioural intervention sessions. This standard treatment may include medication, counselling, psychological therapy and/or referrals to a range of specialist mental health treatments or services.</p>
                <p>The results of this study will be disseminated as widely as possible into the scientific and broader community. This may include publication in peer-reviewed journals, scholarly book chapters, presentation at conferences and publication in conference proceedings. In accordance with NHMRC policy, publications arising from this study will be deposited into an open access institutional repository, where possible. It is also intended for results to be disseminated into the wider community in a format appropriate for a lay audience, through links including the BMC website and social media, as well as newsletters.</p>
              </sec>
              <sec id="s2-19">
                <title>Trial status</title>
                <p>The trial has not yet begun recruitment.</p>
              </sec>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e157">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2022-064682.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e158">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2022-064682.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> CW has developed this pilot clinical trial as part of her PhD research project and drafted this original manuscript with input from other authors. IBH assisted with the design of the study. AN, NZ, JSC, YJCS, CM, BH, JCC, SH, DK and EMS were all involved with modifications to the design of the study and with drafting of this paper. All authors have read and approved the final manuscript.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> This project is an investigator-initiated study, sponsored by the University of Sydney and supported by philanthropic funding, for which donor(s) are families affected by mental illness who wish to remain anonymous. This study was also partially funded by a philanthropic PhD scholarship (The Liu McCabe Family Scholarship awarded to CW), a National Health &amp; Medical Research Council Australia Fellowship (No. 511921, awarded to IBH), a National Health &amp; Medical Research Council Emerging Leadership Fellowship (awarded to JJC) and a philanthropic fellowship (the Caroline Quinn Research Grant awarded to JSC). The funders of this study had no involvement in the: study design; collection, analysis and reporting of the data; writing of the report; or decision to submit the paper for publication.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> Professor IBH was an inaugural Commissioner on Australia’s National Mental Health Commission (2012–2018). He is the Co-Director, Health and Policy at the Brain and Mind Centre (BMC) University of Sydney. The BMC operates early-intervention youth services at Camperdown under contract to headspace. He is the Chief Scientific Advisor to, and a 5% equity shareholder in, InnoWell Pty LTd. InnoWell was formed by the University of Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30M Australian Government-funded Project Synergy (2017–2020; a 3-year program for the transformation of mental health services) and to lead transformation of mental health services internationally through the use of innovative technologies. A/Prof EMS is Principal Research Fellow at the Brain and Mind Centre, The University of Sydney. She is Discipline Leader of Adult Mental Health, School of Medicine, University of Notre Dame, and a Consultant Psychiatrist. She was the Medical Director, Young Adult Mental Health Unit, St Vincent’s Hospital Darlinghurst until January 2021. She has received honoraria for educational seminars related to the clinical management of depressive disorders supported by Servier and Eli-Lilly pharmaceuticals. She has participated in a national advisory board for the antidepressant compound Pristiq, manufactured by Pfizer. She was the National Coordinator of an antidepressant trial sponsored by Servier.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were involved in the design, or conduct, or reporting or dissemination plans of this research. Refer to the Methods section for further details.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chao</surname><given-names>AM</given-names></string-name>, <string-name><surname>Wadden</surname><given-names>TA</given-names></string-name>, <string-name><surname>Berkowitz</surname><given-names>RI</given-names></string-name></person-group>. <article-title>Obesity in adolescents with psychiatric disorders</article-title>. <source>Curr Psychiatry Rep</source><year>2019</year>;<volume>21</volume>:<elocation-id>3</elocation-id>. <pub-id pub-id-type="doi">10.1007/s11920-019-0990-7</pub-id><pub-id pub-id-type="pmid">30661128</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>EM</given-names></string-name>, <string-name><surname>Hermens</surname><given-names>DF</given-names></string-name>, <string-name><surname>White</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Body mass, cardiovascular risk and metabolic characteristics of young persons presenting for mental healthcare in Sydney, Australia</article-title>. <source>BMJ Open</source><year>2015</year>;<volume>5</volume>:<elocation-id>e007066</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2014-007066</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>EM</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>JS</given-names></string-name>, <string-name><surname>Iorfino</surname><given-names>F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>What is the prevalence, and what are the clinical correlates, of insulin resistance in young people presenting for mental health care? A cross-sectional study</article-title>. <source>BMJ Open</source><year>2019</year>;<volume>9</volume>:<elocation-id>e025674</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2018-025674</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Wilson</surname><given-names>C</given-names></string-name>, <string-name><surname>Van Deusen</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metabolic syndrome in child and adolescent psychiatry</article-title>. <source>Psychiatric Annals</source><year>2020</year>;<volume>50</volume>:<fpage>326</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.3928/00485713-20200630-01</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Firth</surname><given-names>J</given-names></string-name>, <string-name><surname>Siddiqi</surname><given-names>N</given-names></string-name>, <string-name><surname>Koyanagi</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The lancet psychiatry commission: a blueprint for protecting physical health in people with mental illness</article-title>. <source>Lancet Psychiatry</source><year>2019</year>;<volume>6</volume>:<fpage>675</fpage>–<lpage>712</lpage>. <pub-id pub-id-type="doi">10.1016/S2215-0366(19)30132-4</pub-id><pub-id pub-id-type="pmid">31324560</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Iturralde</surname><given-names>E</given-names></string-name>, <string-name><surname>Slama</surname><given-names>N</given-names></string-name>, <string-name><surname>Kline-Simon</surname><given-names>AH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Premature mortality associated with severe mental illness or substance use disorder in an integrated health care system</article-title>. <source>Gen Hosp Psychiatry</source><year>2021</year>;<volume>68</volume>:<fpage>1</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.genhosppsych.2020.11.002</pub-id><pub-id pub-id-type="pmid">33227668</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Carney</surname><given-names>R</given-names></string-name>, <string-name><surname>Firth</surname><given-names>J</given-names></string-name>, <string-name><surname>Pedley</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The clinical and behavioral cardiometabolic risk of children and young people on mental health inpatient units: a systematic review and meta-analysis</article-title>. <source>Gen Hosp Psychiatry</source><year>2021</year>;<volume>70</volume>:<fpage>80</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.genhosppsych.2021.03.007</pub-id><pub-id pub-id-type="pmid">33773375</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smith</surname><given-names>J</given-names></string-name>, <string-name><surname>Griffiths</surname><given-names>LA</given-names></string-name>, <string-name><surname>Band</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cardiometabolic risk in first episode psychosis patients</article-title>. <source>Front Endocrinol (Lausanne)</source><year>2020</year>;<volume>11</volume>:<fpage>564240</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2020.564240</pub-id><pub-id pub-id-type="pmid">33329382</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mannan</surname><given-names>M</given-names></string-name>, <string-name><surname>Mamun</surname><given-names>A</given-names></string-name>, <string-name><surname>Doi</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prospective associations between depression and obesity for adolescent males and females- a systematic review and meta-analysis of longitudinal studies</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<elocation-id>e0157240</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0157240</pub-id><pub-id pub-id-type="pmid">27285386</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Perry</surname><given-names>BI</given-names></string-name>, <string-name><surname>Stochl</surname><given-names>J</given-names></string-name>, <string-name><surname>Upthegrove</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Longitudinal trends in childhood insulin levels and body mass index and associations with risks of psychosis and depression in young adults</article-title>. <source>JAMA Psychiatry</source><year>2021</year>;<volume>78</volume>:<fpage>416</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2020.4180</pub-id><pub-id pub-id-type="pmid">33439216</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vancampfort</surname><given-names>D</given-names></string-name>, <string-name><surname>Firth</surname><given-names>J</given-names></string-name>, <string-name><surname>Schuch</surname><given-names>FB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis</article-title>. <source>World Psychiatry</source><year>2017</year>;<volume>16</volume>:<fpage>308</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20458</pub-id><pub-id pub-id-type="pmid">28941119</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Teasdale</surname><given-names>SB</given-names></string-name>, <string-name><surname>Ward</surname><given-names>PB</given-names></string-name>, <string-name><surname>Samaras</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Dietary intake of people with severe mental illness: systematic review and meta-analysis</article-title>. <source>Br J Psychiatry</source><year>2019</year>;<volume>214</volume>:<fpage>251</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.2019.20</pub-id><pub-id pub-id-type="pmid">30784395</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname><given-names>CE</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>JS</given-names></string-name>, <string-name><surname>Song</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Associations between 24-h sleep–wake patterns and cardiometabolic risk factors in youth seeking mental health care</article-title>. <source>Sleep Biol Rhythms</source><year>2021</year>;<volume>19</volume>:<fpage>337</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1007/s41105-021-00314-z</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Correll</surname><given-names>CU</given-names></string-name>, <string-name><surname>Manu</surname><given-names>P</given-names></string-name>, <string-name><surname>Olshanskiy</surname><given-names>V</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents</article-title>. <source>JAMA</source><year>2009</year>;<volume>302</volume>:<fpage>1765</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2009.1549</pub-id><pub-id pub-id-type="pmid">19861668</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rena</surname><given-names>G</given-names></string-name>, <string-name><surname>Hardie</surname><given-names>DG</given-names></string-name>, <string-name><surname>Pearson</surname><given-names>ER</given-names></string-name></person-group>. <article-title>The mechanisms of action of metformin</article-title>. <source>Diabetologia</source><year>2017</year>;<volume>60</volume>:<fpage>1577</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1007/s00125-017-4342-z</pub-id><pub-id pub-id-type="pmid">28776086</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McDonagh</surname><given-names>MS</given-names></string-name>, <string-name><surname>Selph</surname><given-names>S</given-names></string-name>, <string-name><surname>Ozpinar</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger</article-title>. <source>JAMA Pediatr</source><year>2014</year>;<volume>168</volume>:<fpage>178</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1001/jamapediatrics.2013.4200</pub-id><pub-id pub-id-type="pmid">24343296</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>X</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effects of metformin on insulin resistance in overweight or obese children and adolescents: a PRISMA-compliant systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Medicine (Baltimore)</source><year>2019</year>;<volume>98</volume>:<elocation-id>e14249</elocation-id>. <pub-id pub-id-type="doi">10.1097/MD.0000000000014249</pub-id><pub-id pub-id-type="pmid">30681616</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname><given-names>MH</given-names></string-name>, <string-name><surname>Kinra</surname><given-names>S</given-names></string-name>, <string-name><surname>Ward</surname><given-names>KJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin for obesity in children and adolescents: a systematic review</article-title>. <source>Diabetes Care</source><year>2009</year>;<volume>32</volume>:<fpage>1743</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.2337/dc09-0258</pub-id><pub-id pub-id-type="pmid">19502540</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lentferink</surname><given-names>YE</given-names></string-name>, <string-name><surname>Knibbe</surname><given-names>CAJ</given-names></string-name>, <string-name><surname>van der Vorst</surname><given-names>MMJ</given-names></string-name></person-group>. <article-title>Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: a systematic review</article-title>. <source>Drugs</source><year>2018</year>;<volume>78</volume>:<fpage>1887</fpage>–<lpage>901</lpage>. <pub-id pub-id-type="doi">10.1007/s40265-018-1025-0</pub-id><pub-id pub-id-type="pmid">30511324</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Correll</surname><given-names>CU</given-names></string-name>, <string-name><surname>Sikich</surname><given-names>L</given-names></string-name>, <string-name><surname>Reeves</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin add-on vs. antipsychotic switch vs. continued antipsychotic treatment plus healthy lifestyle education in overweight or obese youth with severe mental illness: results from the impact trial</article-title>. <source>World Psychiatry</source><year>2020</year>;<volume>19</volume>:<fpage>69</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20714</pub-id><pub-id pub-id-type="pmid">31922663</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Levy-Shraga</surname><given-names>Y</given-names></string-name>, <string-name><surname>Madi</surname><given-names>LR</given-names></string-name>, <string-name><surname>Shalev</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effectiveness of metformin for weight reduction in children and adolescents treated with mixed dopamine and serotonin receptor antagonists: a naturalistic cohort study</article-title>. <source>J Child Adolesc Psychopharmacol</source><year>2021</year>;<volume>31</volume>:<fpage>376</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2021.0006</pub-id><pub-id pub-id-type="pmid">33887146</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wu</surname><given-names>R-R</given-names></string-name>, <string-name><surname>Zhao</surname><given-names>J-P</given-names></string-name>, <string-name><surname>Guo</surname><given-names>X-F</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study</article-title>. <source>Am J Psychiatry</source><year>2008</year>;<volume>165</volume>:<fpage>352</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2007.07010079</pub-id><pub-id pub-id-type="pmid">18245179</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ellul</surname><given-names>P</given-names></string-name>, <string-name><surname>Delorme</surname><given-names>R</given-names></string-name>, <string-name><surname>Cortese</surname><given-names>S</given-names></string-name></person-group>. <article-title>Metformin for weight gain associated with second-generation antipsychotics in children and adolescents: a systematic review and meta-analysis</article-title>. <source>CNS Drugs</source><year>2018</year>;<volume>32</volume>:<fpage>1103</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1007/s40263-018-0571-z</pub-id><pub-id pub-id-type="pmid">30238318</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shin</surname><given-names>L</given-names></string-name>, <string-name><surname>Bregman</surname><given-names>H</given-names></string-name>, <string-name><surname>Breeze</surname><given-names>JL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin for weight control in pediatric patients on atypical antipsychotic medication</article-title>. <source>J Child Adolesc Psychopharmacol</source><year>2009</year>;<volume>19</volume>:<fpage>275</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1089/cap.2008.094</pub-id><pub-id pub-id-type="pmid">19519262</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vancampfort</surname><given-names>D</given-names></string-name>, <string-name><surname>Firth</surname><given-names>J</given-names></string-name>, <string-name><surname>Correll</surname><given-names>CU</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The impact of pharmacological and non-pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta-review of meta-analyses of randomized controlled trials</article-title>. <source>World Psychiatry</source><year>2019</year>;<volume>18</volume>:<fpage>53</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20614</pub-id><pub-id pub-id-type="pmid">30600626</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Erensoy</surname><given-names>H</given-names></string-name>, <string-name><surname>Niafar</surname><given-names>M</given-names></string-name>, <string-name><surname>Ghafarzadeh</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome</article-title>. <source>Gynecol Endocrinol</source><year>2019</year>;<volume>35</volume>:<fpage>72</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1080/09513590.2018.1498476</pub-id><pub-id pub-id-type="pmid">30182764</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname><given-names>M</given-names></string-name>, <string-name><surname>Mi</surname><given-names>J</given-names></string-name>, <string-name><surname>Jiang</surname><given-names>Q-M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus</article-title>. <source>Clin Exp Pharmacol Physiol</source><year>2014</year>;<volume>41</volume>:<fpage>650</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/1440-1681.12265</pub-id><pub-id pub-id-type="pmid">24862430</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kulkarni</surname><given-names>AS</given-names></string-name>, <string-name><surname>Gubbi</surname><given-names>S</given-names></string-name>, <string-name><surname>Barzilai</surname><given-names>N</given-names></string-name></person-group>. <article-title>Benefits of metformin in attenuating the hallmarks of aging</article-title>. <source>Cell Metabolism</source><year>2020</year>. <pub-id pub-id-type="doi">10.1016/j.cmet.2020.04.001</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bersani</surname><given-names>FS</given-names></string-name>, <string-name><surname>Biondi</surname><given-names>M</given-names></string-name>, <string-name><surname>Coviello</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Psychoeducational intervention focused on healthy living improves psychopathological severity and lifestyle quality in psychiatric patients: preliminary findings from a controlled study</article-title>. <source>J Ment Health</source><year>2017</year>;<volume>26</volume>:<fpage>271</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1080/09638237.2017.1294741</pub-id><pub-id pub-id-type="pmid">28558488</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De Rosa</surname><given-names>C</given-names></string-name>, <string-name><surname>Sampogna</surname><given-names>G</given-names></string-name>, <string-name><surname>Luciano</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Improving physical health of patients with severe mental disorders: a critical review of lifestyle psychosocial interventions</article-title>. <source>Expert Review of Neurotherapeutics</source><year>2017</year>;<volume>17</volume>:<fpage>667</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1080/14737175.2017.1325321</pub-id><pub-id pub-id-type="pmid">28468528</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rönngren</surname><given-names>Y</given-names></string-name>, <string-name><surname>Björk</surname><given-names>A</given-names></string-name>, <string-name><surname>Audulv</surname><given-names>Å</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Educational nurse-led lifestyle intervention for persons with mental illness</article-title>. <source>Int J Ment Health Nurs</source><year>2018</year>;<volume>27</volume>:<fpage>1022</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1111/inm.12410</pub-id><pub-id pub-id-type="pmid">29171905</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fiorillo</surname><given-names>A</given-names></string-name>, <string-name><surname>Pompili</surname><given-names>M</given-names></string-name>, <string-name><surname>Luciano</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reducing the mortality gap in people with severe mental disorders: the role of lifestyle psychosocial interventions</article-title>. <source>Front Psychiatry</source><year>2019</year>;<volume>10</volume>. <pub-id pub-id-type="doi">10.3389/fpsyt.2018.00463</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Taylor</surname><given-names>CI</given-names></string-name>, <string-name><surname>Tompsett</surname><given-names>C</given-names></string-name>, <string-name><surname>Sanders</surname><given-names>R</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effectiveness of structured exercise programmes on psychological and physiological outcomes for patients with psychotic disorders: a systematic review and meta-analysis</article-title>. <source>Int J Sport Exerc Psychol</source><year>2020</year>;<volume>18</volume>:<fpage>336</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1080/1612197X.2018.1519838</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goracci</surname><given-names>A</given-names></string-name>, <string-name><surname>Rucci</surname><given-names>P</given-names></string-name>, <string-name><surname>Forgione</surname><given-names>RN</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development, acceptability and efficacy of a standardized healthy lifestyle intervention in recurrent depression</article-title>. <source>J Affect Disord</source><year>2016</year>;<volume>196</volume>:<fpage>20</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2016.02.034</pub-id><pub-id pub-id-type="pmid">26897454</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Atabek</surname><given-names>ME</given-names></string-name>, <string-name><surname>Pirgon</surname><given-names>O</given-names></string-name></person-group>. <article-title>Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial</article-title>. <source>J Pediatr Endocrinol Metab</source><year>2008</year>;<volume>21</volume>:<fpage>339</fpage>–<lpage>48</lpage>. <pub-id pub-id-type="doi">10.1515/jpem.2008.21.4.339</pub-id><pub-id pub-id-type="pmid">18556965</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarson</surname><given-names>CL</given-names></string-name>, <string-name><surname>Mahmud</surname><given-names>FH</given-names></string-name>, <string-name><surname>Baker</surname><given-names>JE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin in combination with structured lifestyle intervention improved body mass index in obese adolescents, but did not improve insulin resistance</article-title>. <source>Endocrine</source><year>2009</year>;<volume>36</volume>:<fpage>141</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s12020-009-9196-9</pub-id><pub-id pub-id-type="pmid">19387874</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Clarson</surname><given-names>CL</given-names></string-name>, <string-name><surname>Brown</surname><given-names>HK</given-names></string-name>, <string-name><surname>De Jesus</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of a comprehensive, intensive lifestyle intervention combined with metformin extended release in obese adolescents</article-title>. <source>Int Sch Res Notices</source><year>2014</year>;<volume>2014</volume>:<elocation-id>659410</elocation-id>. <pub-id pub-id-type="doi">10.1155/2014/659410</pub-id><pub-id pub-id-type="pmid">27433488</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Love-Osborne</surname><given-names>K</given-names></string-name>, <string-name><surname>Sheeder</surname><given-names>J</given-names></string-name>, <string-name><surname>Zeitler</surname><given-names>P</given-names></string-name></person-group>. <article-title>Addition of metformin to a lifestyle modification program in adolescents with insulin resistance</article-title>. <source>J Pediatr</source><year>2008</year>;<volume>152</volume>:<fpage>817</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpeds.2008.01.018</pub-id><pub-id pub-id-type="pmid">18492523</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mauras</surname><given-names>N</given-names></string-name>, <string-name><surname>DelGiorno</surname><given-names>C</given-names></string-name>, <string-name><surname>Hossain</surname><given-names>J</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin use in children with obesity and normal glucose tolerance -- effects on cardiovascular markers and intrahepatic fat</article-title>. <source>J Pediatr Endocrinol Metab</source><year>2012</year>;<volume>25</volume>:<fpage>33</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1515/jpem-2011-0450</pub-id><pub-id pub-id-type="pmid">22570948</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wiegand</surname><given-names>S</given-names></string-name>, <string-name><surname>l’Allemand</surname><given-names>D</given-names></string-name>, <string-name><surname>Hübel</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin and placebo therapy both improve weight management and fasting insulin in obese insulin-resistant adolescents: a prospective, placebo-controlled, randomized study</article-title>. <source>Eur J Endocrinol</source><year>2010</year>;<volume>163</volume>:<fpage>585</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1530/EJE-10-0570</pub-id><pub-id pub-id-type="pmid">20639355</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Warnakulasuriya</surname><given-names>LS</given-names></string-name>, <string-name><surname>Fernando</surname><given-names>MMA</given-names></string-name>, <string-name><surname>Adikaram</surname><given-names>AVN</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin in the management of childhood obesity: a randomized control trial</article-title>. <source>Child Obes</source><year>2018</year>;<volume>14</volume>:<fpage>553</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1089/chi.2018.0043</pub-id><pub-id pub-id-type="pmid">30070925</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname><given-names>DM</given-names></string-name>, <string-name><surname>Abrams</surname><given-names>SH</given-names></string-name>, <string-name><surname>Aye</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up</article-title>. <source>Arch Pediatr Adolesc Med</source><year>2010</year>;<volume>164</volume>:<fpage>116</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1001/archpediatrics.2009.264</pub-id><pub-id pub-id-type="pmid">20124139</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van der Aa</surname><given-names>MP</given-names></string-name>, <string-name><surname>Elst</surname><given-names>MAJ</given-names></string-name>, <string-name><surname>van de Garde</surname><given-names>EMW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial</article-title>. <source>Nutr Diabetes</source><year>2016</year>;<volume>6</volume>:<elocation-id>e228</elocation-id>. <pub-id pub-id-type="doi">10.1038/nutd.2016.37</pub-id><pub-id pub-id-type="pmid">27571249</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fu</surname><given-names>J-F</given-names></string-name>, <string-name><surname>Liang</surname><given-names>L</given-names></string-name>, <string-name><surname>Zou</surname><given-names>C-C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Prevalence of the metabolic syndrome in zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention</article-title>. <source>Int J Obes (Lond)</source><year>2007</year>;<volume>31</volume>:<fpage>15</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ijo.0803453</pub-id><pub-id pub-id-type="pmid">16953257</pub-id></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hui</surname><given-names>F</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ren</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Role of metformin in overweight and obese people without diabetes: a systematic review and network meta-analysis</article-title>. <source>Eur J Clin Pharmacol</source><year>2019</year>;<volume>75</volume>:<fpage>437</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1007/s00228-018-2593-3</pub-id><pub-id pub-id-type="pmid">30511328</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Marques</surname><given-names>P</given-names></string-name>, <string-name><surname>Limbert</surname><given-names>C</given-names></string-name>, <string-name><surname>Oliveira</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin effectiveness and safety in the management of overweight/obese nondiabetic children and adolescents: metabolic benefits of the continuous exposure to metformin at 12 and 24 months</article-title>. <source>Int J Adolesc Med Health</source><year>2016</year>;<volume>29</volume>. <pub-id pub-id-type="doi">10.1515/ijamh-2015-0110</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Health AGDo</collab></person-group>. <article-title>Physical activity and exercise guidelines for all australians</article-title>. <year>2021</year>. <comment>Available</comment>: <uri xlink:href="https://www.health.gov.au/health-topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians">https://www.health.gov.au/health-topics/physical-activity-and-exercise/physical-activity-and-exercise-guidelines-for-all-australians</uri></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>Australian Government Department of Health and Ageing</collab></person-group>. <source>Australian guide to healthy eating</source>. <year>2017</year>.</mixed-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Robillard</surname><given-names>R</given-names></string-name>, <string-name><surname>Hermens</surname><given-names>DF</given-names></string-name>, <string-name><surname>Naismith</surname><given-names>SL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Ambulatory sleep-wake patterns and variability in young people with emerging mental disorders</article-title> [<comment>In Press</comment>]. <source>J Psychiatry Neurosci</source>
<year>2014</year>.</mixed-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harvey</surname><given-names>AG</given-names></string-name>, <string-name><surname>Mullin</surname><given-names>BC</given-names></string-name>, <string-name><surname>Hinshaw</surname><given-names>SP</given-names></string-name></person-group>. <article-title>Sleep and circadian rhythms in children and adolescents with bipolar disorder</article-title>. <source>Dev Psychopathol</source><year>2006</year>;<volume>18</volume>:<fpage>1147</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1017/S095457940606055X</pub-id><pub-id pub-id-type="pmid">17064432</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cousins</surname><given-names>JC</given-names></string-name>, <string-name><surname>Whalen</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Dahl</surname><given-names>RE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The bidirectional association between daytime affect and nighttime sleep in youth with anxiety and depression</article-title>. <source>J Pediatr Psychol</source><year>2011</year>;<volume>36</volume>:<fpage>969</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1093/jpepsy/jsr036</pub-id><pub-id pub-id-type="pmid">21795377</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Minassian</surname><given-names>A</given-names></string-name>, <string-name><surname>Henry</surname><given-names>BL</given-names></string-name>, <string-name><surname>Geyer</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The quantitative assessment of motor activity in mania and schizophrenia</article-title>. <source>J Affect Disord</source><year>2010</year>;<volume>120</volume>:<fpage>200</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2009.04.018</pub-id><pub-id pub-id-type="pmid">19435640</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rohleder</surname><given-names>C</given-names></string-name>, <string-name><surname>Song</surname><given-names>YJC</given-names></string-name>, <string-name><surname>Crouse</surname><given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Youth mental health tracker: protocol to establish a longitudinal cohort and research database for young people attending Australian mental health services</article-title>. <source>BMJ Open</source><year>2020</year>;<volume>10</volume>:<elocation-id>e035379</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2019-035379</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Soliman</surname><given-names>A</given-names></string-name>, <string-name><surname>De Sanctis</surname><given-names>V</given-names></string-name>, <string-name><surname>Alaaraj</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The clinical application of metformin in children and adolescents: a short update</article-title>. <source>Acta Biomed</source><year>2020</year>;<volume>91</volume>:<elocation-id>e2020086</elocation-id>. <pub-id pub-id-type="doi">10.23750/abm.v91i3.10127</pub-id><pub-id pub-id-type="pmid">32921782</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fitzgerald</surname><given-names>I</given-names></string-name>, <string-name><surname>O’Connell</surname><given-names>J</given-names></string-name>, <string-name><surname>Keating</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using grade methodology</article-title>. <source>Evid Based Ment Health</source><year>2022</year>;<volume>25</volume>:<fpage>15</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1136/ebmental-2021-300291</pub-id><pub-id pub-id-type="pmid">34588212</pub-id></mixed-citation>
              </ref>
              <ref id="R56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>Purcell</surname><given-names>R</given-names></string-name>, <string-name><surname>Hickie</surname><given-names>IB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical staging: a heuristic model for psychiatry and youth mental health</article-title>. <source>Med J Aust</source><year>2007</year>;<volume>187</volume>:<fpage>S40</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.5694/j.1326-5377.2007.tb01335.x</pub-id><pub-id pub-id-type="pmid">17908024</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickie</surname><given-names>IB</given-names></string-name>, <string-name><surname>Scott</surname><given-names>EM</given-names></string-name>, <string-name><surname>Hermens</surname><given-names>DF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Applying clinical staging to young people who present for mental health care</article-title>. <source>Early Interv Psychiatry</source><year>2013</year>;<volume>7</volume>:<fpage>31</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1111/j.1751-7893.2012.00366.x</pub-id><pub-id pub-id-type="pmid">22672533</pub-id></mixed-citation>
              </ref>
              <ref id="R58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wilson</surname><given-names>C</given-names></string-name>, <string-name><surname>Nichles</surname><given-names>A</given-names></string-name>, <string-name><surname>Zmicerevska</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effect of an online healthy lifestyle psychoeducation programme to improve cardiometabolic outcomes and affective symptoms in youth receiving mental health care: study protocol for a pilot clinical trial</article-title>. <source>BMJ Open</source><year>2021</year>;<volume>11</volume>:<elocation-id>e044977</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2020-044977</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <label>59</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>American Psychiatric Association</collab></person-group>. <source>Diagnostic and statistical manual of mental disorders</source>. <edition>5th ed</edition>. <publisher-loc>Arlington</publisher-loc>, <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="R60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Overall</surname><given-names>JE</given-names></string-name>, <string-name><surname>Gorham</surname><given-names>DR</given-names></string-name></person-group>. <article-title>The brief psychiatric rating scale</article-title>. <source>Psychol Rep</source><year>1962</year>;<volume>10</volume>:<fpage>799</fpage>–<lpage>812</lpage>. <pub-id pub-id-type="doi">10.2466/pr0.1962.10.3.799</pub-id></mixed-citation>
              </ref>
              <ref id="R61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <string-name><surname>Hickie</surname><given-names>IB</given-names></string-name>, <string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions</article-title>. <source>Aust N Z J Psychiatry</source><year>2006</year>;<volume>40</volume>:<fpage>616</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1080/j.1440-1614.2006.01860.x</pub-id><pub-id pub-id-type="pmid">16866756</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Scott</surname><given-names>J</given-names></string-name>, <string-name><surname>Leboyer</surname><given-names>M</given-names></string-name>, <string-name><surname>Hickie</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Clinical staging in psychiatry: a cross-cutting model of diagnosis with heuristic and practical value</article-title>. <source>Br J Psychiatry</source><year>2013</year>;<volume>202</volume>:<fpage>243</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.bp.112.110858</pub-id><pub-id pub-id-type="pmid">23549937</pub-id></mixed-citation>
              </ref>
              <ref id="R63">
                <label>63</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickie</surname><given-names>IB</given-names></string-name>, <string-name><surname>Scott</surname><given-names>J</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name></person-group>. <article-title>Clinical staging for mental disorders: a new development in diagnostic practice in mental health</article-title>. <source>Med J Aust</source><year>2013</year>;<volume>198</volume>:<fpage>461</fpage>–<lpage>2</lpage>. <pub-id pub-id-type="doi">10.5694/mja13.10431</pub-id><pub-id pub-id-type="pmid">23682872</pub-id></mixed-citation>
              </ref>
              <ref id="R64">
                <label>64</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hickie</surname><given-names>IB</given-names></string-name>, <string-name><surname>Hermens</surname><given-names>DF</given-names></string-name>, <string-name><surname>Naismith</surname><given-names>SL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Evaluating differential developmental trajectories to adolescent-onset mood and psychotic disorders</article-title>. <source>BMC Psychiatry</source><year>2013</year>;<volume>13</volume>:<elocation-id>303</elocation-id>. <pub-id pub-id-type="doi">10.1186/1471-244X-13-303</pub-id><pub-id pub-id-type="pmid">24215120</pub-id></mixed-citation>
              </ref>
              <ref id="R65">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Busner</surname><given-names>J</given-names></string-name>, <string-name><surname>Targum</surname><given-names>SD</given-names></string-name></person-group>. <article-title>The clinical global impressions scale: applying a research tool in clinical practice</article-title>. <source>Psychiatry (Edgmont)</source><year>2007</year>;<volume>4</volume>:<fpage>28</fpage>–<lpage>37</lpage>.</mixed-citation>
              </ref>
              <ref id="R66">
                <label>66</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Young</surname><given-names>RC</given-names></string-name>, <string-name><surname>Biggs</surname><given-names>JT</given-names></string-name>, <string-name><surname>Ziegler</surname><given-names>VE</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A rating scale for mania: reliability, validity and sensitivity</article-title>. <source>Br J Psychiatry</source><year>1978</year>;<volume>133</volume>:<fpage>429</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.133.5.429</pub-id><pub-id pub-id-type="pmid">728692</pub-id></mixed-citation>
              </ref>
              <ref id="R67">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenbaum</surname><given-names>S</given-names></string-name>, <string-name><surname>Ward</surname><given-names>PB</given-names></string-name>, <collab>International Working Group</collab></person-group>. <article-title>The simple physical activity questionnaire</article-title>. <source>Lancet Psychiatry</source><year>2016</year>;<volume>3</volume>:<elocation-id>e1</elocation-id>. <pub-id pub-id-type="doi">10.1016/S2215-0366(15)00496-4</pub-id></mixed-citation>
              </ref>
              <ref id="R68">
                <label>68</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yung</surname><given-names>AR</given-names></string-name>, <string-name><surname>Yuen</surname><given-names>HP</given-names></string-name>, <string-name><surname>McGorry</surname><given-names>PD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Mapping the onset of psychosis: the comprehensive assessment of at-risk mental states</article-title>. <source>Aust N Z J Psychiatry</source><year>2005</year>;<volume>39</volume>:<fpage>964</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1080/j.1440-1614.2005.01714.x</pub-id><pub-id pub-id-type="pmid">16343296</pub-id></mixed-citation>
              </ref>
              <ref id="R69">
                <label>69</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kessler</surname><given-names>RC</given-names></string-name>, <string-name><surname>Andrews</surname><given-names>G</given-names></string-name>, <string-name><surname>Colpe</surname><given-names>LJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Short screening scales to monitor population prevalences and trends in non-specific psychological distress</article-title>. <source>Psychol Med</source><year>2002</year>;<volume>32</volume>:<fpage>959</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1017/s0033291702006074</pub-id><pub-id pub-id-type="pmid">12214795</pub-id></mixed-citation>
              </ref>
              <ref id="R70">
                <label>70</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrews</surname><given-names>G</given-names></string-name>, <string-name><surname>Slade</surname><given-names>T</given-names></string-name></person-group>. <article-title>Interpreting scores on the kessler psychological distress scale (K10)</article-title>. <source>Aust N Z J Public Health</source><year>2001</year>;<volume>25</volume>:<fpage>494</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1111/j.1467-842x.2001.tb00310.x</pub-id><pub-id pub-id-type="pmid">11824981</pub-id></mixed-citation>
              </ref>
              <ref id="R71">
                <label>71</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Craig</surname><given-names>CL</given-names></string-name>, <string-name><surname>Marshall</surname><given-names>AL</given-names></string-name>, <string-name><surname>Sjöström</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>International physical activity questionnaire: 12-country reliability and validity</article-title>. <source>Med Sci Sports Exerc</source><year>2003</year>;<volume>35</volume>:<fpage>1381</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1249/01.MSS.0000078924.61453.FB</pub-id><pub-id pub-id-type="pmid">12900694</pub-id></mixed-citation>
              </ref>
              <ref id="R72">
                <label>72</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Booth</surname><given-names>M</given-names></string-name></person-group>. <article-title>Assessment of physical activity: an international perspective</article-title>. <source>Res Q Exerc Sport</source><year>2000</year>;<volume>71 Suppl 2</volume>:<fpage>114</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1080/02701367.2000.11082794</pub-id><pub-id pub-id-type="pmid">25680021</pub-id></mixed-citation>
              </ref>
              <ref id="R73">
                <label>73</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berryman</surname><given-names>C</given-names></string-name>, <string-name><surname>McAuley</surname><given-names>JH</given-names></string-name>, <string-name><surname>Moseley</surname><given-names>LG</given-names></string-name></person-group>. <article-title>Sphere 12 screening questionnaire</article-title>. <source>J Physiother</source><year>2012</year>;<volume>58</volume>:<fpage>273</fpage>. <pub-id pub-id-type="doi">10.1016/S1836-9553(12)70133-9</pub-id><pub-id pub-id-type="pmid">23177234</pub-id></mixed-citation>
              </ref>
              <ref id="R74">
                <label>74</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Smyth</surname><given-names>C</given-names></string-name></person-group>. <article-title>The Pittsburgh sleep quality index (PSQI)</article-title>. <source>J Gerontol Nurs</source><year>1999</year>;<volume>25</volume>:<fpage>10</fpage>–<lpage>1</lpage>. <pub-id pub-id-type="doi">10.3928/0098-9134-19991201-10</pub-id></mixed-citation>
              </ref>
              <ref id="R75">
                <label>75</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Shahid</surname><given-names>A</given-names></string-name>, <string-name><surname>Wilkinson</surname><given-names>K</given-names></string-name>, <string-name><surname>Marcu</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <source>Munich chronotype questionnaire (MCTQ). STOP, THAT and one hundred other sleep scales</source>. <publisher-name>Springer</publisher-name>, <year>2011</year>: <fpage>245</fpage>–<lpage>7</lpage>.</mixed-citation>
              </ref>
              <ref id="R76">
                <label>76</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Morin</surname><given-names>CM</given-names></string-name></person-group>. <source>Insomnia: psychological assessment and management</source>. <publisher-name>Guilford press</publisher-name>, <year>1993</year>.</mixed-citation>
              </ref>
              <ref id="R77">
                <label>77</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Spijker</surname><given-names>BAJ</given-names></string-name>, <string-name><surname>Batterham</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Calear</surname><given-names>AL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The suicidal ideation attributes scale (SIDAS): community-based validation study of a new scale for the measurement of suicidal ideation</article-title>. <source>Suicide Life Threat Behav</source><year>2014</year>;<volume>44</volume>:<fpage>408</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1111/sltb.12084</pub-id><pub-id pub-id-type="pmid">24612048</pub-id></mixed-citation>
              </ref>
              <ref id="R78">
                <label>78</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rush</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Trivedi</surname><given-names>MH</given-names></string-name>, <string-name><surname>Ibrahim</surname><given-names>HM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The 16-item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression</article-title>. <source>Biol Psychiatry</source><year>2003</year>;<volume>54</volume>:<fpage>573</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/s0006-3223(02)01866-8</pub-id><pub-id pub-id-type="pmid">12946886</pub-id></mixed-citation>
              </ref>
              <ref id="R79">
                <label>79</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Norman</surname><given-names>SB</given-names></string-name>, <string-name><surname>Cissell</surname><given-names>SH</given-names></string-name>, <string-name><surname>Means-Christensen</surname><given-names>AJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and validation of an overall anxiety severity and impairment scale (OASIS)</article-title>. <source>Depress Anxiety</source><year>2006</year>;<volume>23</volume>:<fpage>245</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/da.20182</pub-id><pub-id pub-id-type="pmid">16688739</pub-id></mixed-citation>
              </ref>
              <ref id="R80">
                <label>80</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Humeniuk</surname><given-names>R</given-names></string-name>, <string-name><surname>Ali</surname><given-names>R</given-names></string-name>, <string-name><surname>Babor</surname><given-names>TF</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Validation of the alcohol, smoking and substance involvement screening test (assist)</article-title>. <source>Addiction</source><year>2008</year>;<volume>103</volume>:<fpage>1039</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.2007.02114.x</pub-id><pub-id pub-id-type="pmid">18373724</pub-id></mixed-citation>
              </ref>
              <ref id="R81">
                <label>81</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Group</surname><given-names>WAW</given-names></string-name></person-group>. <article-title>The alcohol, smoking and substance involvement screening test (assist): development, reliability and feasibility</article-title>. <source>Addiction</source><year>2002</year>;<volume>97</volume>:<fpage>1183</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1046/j.1360-0443.2002.00185.x</pub-id><pub-id pub-id-type="pmid">12199834</pub-id></mixed-citation>
              </ref>
              <ref id="R82">
                <label>82</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bush</surname><given-names>K</given-names></string-name>, <string-name><surname>Kivlahan</surname><given-names>DR</given-names></string-name>, <string-name><surname>McDonell</surname><given-names>MB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The audit alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. ambulatory care quality improvement project (ACQUIP). alcohol use disorders identification test</article-title>. <source>Arch Intern Med</source><year>1998</year>;<volume>158</volume>:<fpage>1789</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1001/archinte.158.16.1789</pub-id><pub-id pub-id-type="pmid">9738608</pub-id></mixed-citation>
              </ref>
              <ref id="R83">
                <label>83</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hay</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Mond</surname><given-names>J</given-names></string-name>, <string-name><surname>Buttner</surname><given-names>P</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Eating disorder behaviors are increasing: findings from two sequential community surveys in South Australia</article-title>. <source>PLoS ONE</source><year>2008</year>;<volume>3</volume>:<elocation-id>e1541</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0001541</pub-id><pub-id pub-id-type="pmid">18253489</pub-id></mixed-citation>
              </ref>
              <ref id="R84">
                <label>84</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchison</surname><given-names>D</given-names></string-name>, <string-name><surname>Hay</surname><given-names>P</given-names></string-name>, <string-name><surname>Slewa-Younan</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The changing demographic profile of eating disorder behaviors in the community</article-title>. <source>BMC Public Health</source><year>2014</year>;<volume>14</volume>:<elocation-id>943</elocation-id>. <pub-id pub-id-type="doi">10.1186/1471-2458-14-943</pub-id><pub-id pub-id-type="pmid">25213544</pub-id></mixed-citation>
              </ref>
              <ref id="R85">
                <label>85</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Rosenberg</surname><given-names>M</given-names></string-name></person-group>. <part-title>Rosenberg self-esteem scale (RSE)</part-title>. In: <source>Acceptance and commitment therapy Measures package, 61</source>. <year>1965</year>: <fpage>18</fpage>.</mixed-citation>
              </ref>
              <ref id="R86">
                <label>86</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsen</surname><given-names>DL</given-names></string-name>, <string-name><surname>Attkisson</surname><given-names>CC</given-names></string-name>, <string-name><surname>Hargreaves</surname><given-names>WA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Assessment of client/patient satisfaction: development of a general scale</article-title>. <source>Eval Program Plann</source><year>1979</year>;<volume>2</volume>:<fpage>197</fpage>–<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1016/0149-7189(79)90094-6</pub-id><pub-id pub-id-type="pmid">10245370</pub-id></mixed-citation>
              </ref>
              <ref id="R87">
                <label>87</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hill</surname><given-names>NR</given-names></string-name>, <string-name><surname>Levy</surname><given-names>JC</given-names></string-name>, <string-name><surname>Matthews</surname><given-names>DR</given-names></string-name></person-group>. <article-title>Expansion of the homeostasis model assessment of β-cell function and insulin resistance to enable clinical trial outcome modeling through the interactive adjustment of physiology and treatment effects: ihoma2</article-title>. <source>Diabetes Care</source><year>2013</year>;<volume>36</volume>:<fpage>2324</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.2337/dc12-0607</pub-id><pub-id pub-id-type="pmid">23564921</pub-id></mixed-citation>
              </ref>
              <ref id="R88">
                <label>88</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Difrancesco</surname><given-names>S</given-names></string-name>, <string-name><surname>Lamers</surname><given-names>F</given-names></string-name>, <string-name><surname>Riese</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sleep, circadian rhythm, and physical activity patterns in depressive and anxiety disorders: a 2-week ambulatory assessment study</article-title>. <source>Depress Anxiety</source><year>2019</year>;<volume>36</volume>:<fpage>975</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/da.22949</pub-id><pub-id pub-id-type="pmid">31348850</pub-id></mixed-citation>
              </ref>
              <ref id="R89">
                <label>89</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schaefer</surname><given-names>CA</given-names></string-name>, <string-name><surname>Nigg</surname><given-names>CR</given-names></string-name>, <string-name><surname>Hill</surname><given-names>JO</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Establishing and evaluating wrist cutpoints for the geneactiv accelerometer in youth</article-title>. <source>Med Sci Sports Exerc</source><year>2014</year>;<volume>46</volume>:<fpage>826</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000000150</pub-id><pub-id pub-id-type="pmid">24121241</pub-id></mixed-citation>
              </ref>
              <ref id="R90">
                <label>90</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hildebrand</surname><given-names>M</given-names></string-name>, <string-name><surname>VAN Hees</surname><given-names>VT</given-names></string-name>, <string-name><surname>Hansen</surname><given-names>BH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Age group comparability of raw accelerometer output from wrist- and hip-worn monitors</article-title>. <source>Med Sci Sports Exerc</source><year>2014</year>;<volume>46</volume>:<fpage>1816</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0000000000000289</pub-id><pub-id pub-id-type="pmid">24887173</pub-id></mixed-citation>
              </ref>
              <ref id="R91">
                <label>91</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Esliger</surname><given-names>DW</given-names></string-name>, <string-name><surname>Rowlands</surname><given-names>AV</given-names></string-name>, <string-name><surname>Hurst</surname><given-names>TL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Validation of the GENEA accelerometer</article-title>. <source>Med Sci Sports Exerc</source><year>2011</year>;<volume>43</volume>:<fpage>1085</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1249/MSS.0b013e31820513be</pub-id><pub-id pub-id-type="pmid">21088628</pub-id></mixed-citation>
              </ref>
              <ref id="R92">
                <label>92</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Hees</surname><given-names>VT</given-names></string-name>, <string-name><surname>Gorzelniak</surname><given-names>L</given-names></string-name>, <string-name><surname>Dean León</surname><given-names>EC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Separating movement and gravity components in an acceleration signal and implications for the assessment of human daily physical activity</article-title>. <source>PLoS ONE</source><year>2013</year>;<volume>8</volume>:<elocation-id>e61691</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061691</pub-id><pub-id pub-id-type="pmid">23626718</pub-id></mixed-citation>
              </ref>
              <ref id="R93">
                <label>93</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>te Lindert</surname><given-names>BHW</given-names></string-name>, <string-name><surname>Van Someren</surname><given-names>EJW</given-names></string-name></person-group>. <article-title>Sleep estimates using microelectromechanical systems (MEMS)</article-title>. <source>Sleep</source><year>2013</year>;<volume>36</volume>:<fpage>781</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.5665/sleep.2648</pub-id><pub-id pub-id-type="pmid">23633761</pub-id></mixed-citation>
              </ref>
              <ref id="R94">
                <label>94</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Hees</surname><given-names>VT</given-names></string-name>, <string-name><surname>Sabia</surname><given-names>S</given-names></string-name>, <string-name><surname>Anderson</surname><given-names>KN</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A novel, open access method to assess sleep duration using A wrist-worn accelerometer</article-title>. <source>PLoS ONE</source><year>2015</year>;<volume>10</volume>:<elocation-id>e0142533</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0142533</pub-id><pub-id pub-id-type="pmid">26569414</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
